Artículo de revista
Multi-feature computational framework for combined signatures of dementia in underrepresented settings
Fecha
2022Registro en:
J. Neural Eng. 19 (2022) 046048
10.1088/1741-2552/ac87d0
Autor
Moguilner, Sebastian
Birba, Agustina
Fittipaldi, Sol
González Campos, Cecilia
Tagliazucchi, Enzo Rodolfo
Reyes, Pablo
Matallana, Diana
Parra, Mario A.
Slachevsky Chonchol, Andrea María
Farías Gontupil, Gonzalo Andrés
Cruzat Grand, Josefina
García, Adolfo
Eyre, Harris A.
La Joie, Renaud
Rabinovici, Gil
Whelan, Robert
Ibáñez, Agustín
Institución
Resumen
Objective. The differential diagnosis of behavioral variant frontotemporal dementia (bvFTD) and
Alzheimer’s disease (AD) remains challenging in underrepresented, underdiagnosed groups,
including Latinos, as advanced biomarkers are rarely available. Recent guidelines for the study of
dementia highlight the critical role of biomarkers. Thus, novel cost-effective complementary
approaches are required in clinical settings. Approach. We developed a novel framework based on a
gradient boosting machine learning classifier, tuned by Bayesian optimization, on a multi-feature
multimodal approach (combining demographic, neuropsychological, magnetic resonance imaging
(MRI), and electroencephalography/functional MRI connectivity data) to characterize
neurodegeneration using site harmonization and sequential feature selection. We assessed 54
bvFTD and 76 AD patients and 152 healthy controls (HCs) from a Latin American consortium
(ReDLat). Main results. The multimodal model yielded high area under the curve classification
values (bvFTD patients vs HCs: 0.93 (±0.01); AD patients vs HCs: 0.95 (±0.01); bvFTD vs AD
patients: 0.92 (±0.01)). The feature selection approach successfully filtered non-informative
multimodal markers (from thousands to dozens). Results. Proved robust against multimodal
heterogeneity, sociodemographic variability, and missing data. Significance. The model accurately
identified dementia subtypes using measures readily available in underrepresented settings, with a
similar performance than advanced biomarkers. This approach, if confirmed and replicated, may
potentially complement clinical assessments in developing countries.